Risetherapeutics
2 known investors
Find your way into Risetherapeutics
Sign up to see every warm intro you have to Risetherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Risetherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.
Founders & leadership
Investors · 2
Related companies · 6
Resolve TherapeuticsBiopharma company developing non-immunosuppressive drugs for autoimmune diseases.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Sarepta TherapeuticsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies working in the same space as Risetherapeutics.
Frequently asked questions
- What does Risetherapeutics do?
- Rise Therapeutics develops oral immunotherapies, called Oral Immune BioModulators, using a synthetic biology-based drug design approach to treat autoimmune diseases and cancer. The company combines immunology research with in-house clinical GMP manufacturing and regulatory expertise to advance its pipeline through clinical validation.
- Who founded Risetherapeutics?
- Risetherapeutics was founded by Gary Fanger.
- Who are Risetherapeutics's investors?
- Risetherapeutics's investors include Maryland TEDCO, TEDCO.



